These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24663501)

  • 1. DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development.
    Shah ED; Fisch BM; Arceci RJ; Buckley JD; Reaman GH; Sorensen PH; Triche TJ; Reynolds CP
    Cancer Chemother Pharmacol; 2014 May; 73(5):1089-93. PubMed ID: 24663501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising targets and drugs in development for colorectal cancer.
    Thompson C; Leong S; Messersmith W
    Semin Oncol; 2011 Aug; 38(4):588-97. PubMed ID: 21810518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical studies in oncology--a challenge for clinical and academic pathology].
    Röcken C
    Dtsch Med Wochenschr; 2013 May; 138(20):1073-6. PubMed ID: 23670265
    [No Abstract]   [Full Text] [Related]  

  • 5. Implementation of mechanism of action biology-driven early drug development for children with cancer.
    Pearson AD; Herold R; Rousseau R; Copland C; Bradley-Garelik B; Binner D; Capdeville R; Caron H; Carleer J; Chesler L; Geoerger B; Kearns P; Marshall LV; Pfister SM; Schleiermacher G; Skolnik J; Spadoni C; Sterba J; van den Berg H; Uttenreuther-Fischer M; Witt O; Norga K; Vassal G;
    Eur J Cancer; 2016 Jul; 62():124-31. PubMed ID: 27258969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinued drugs in 2008: oncology drugs.
    Williams R
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel drugs for promising targets.
    Martell RE; Brooks DG; Wang Y; Wilcoxen K
    Clin Ther; 2013 Sep; 35(9):1271-81. PubMed ID: 24054704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational drugs for pruritus.
    Benecke H; Lotts T; Ständer S
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1167-79. PubMed ID: 23815605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open Targets Platform: supporting systematic drug-target identification and prioritisation.
    Ochoa D; Hercules A; Carmona M; Suveges D; Gonzalez-Uriarte A; Malangone C; Miranda A; Fumis L; Carvalho-Silva D; Spitzer M; Baker J; Ferrer J; Raies A; Razuvayevskaya O; Faulconbridge A; Petsalaki E; Mutowo P; Machlitt-Northen S; Peat G; McAuley E; Ong CK; Mountjoy E; Ghoussaini M; Pierleoni A; Papa E; Pignatelli M; Koscielny G; Karim M; Schwartzentruber J; Hulcoop DG; Dunham I; McDonagh EM
    Nucleic Acids Res; 2021 Jan; 49(D1):D1302-D1310. PubMed ID: 33196847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The path to oncology drug target validation: an industry perspective.
    Cortés-Cros M; Schmelzle T; Stucke VM; Hofmann F
    Methods Mol Biol; 2013; 986():3-13. PubMed ID: 23436402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.
    Wong MS; Sidik SM; Mahmud R; Stanslas J
    Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective.
    Ataman OU; Sambrook SJ; Wilks C; Lloyd A; Taylor AE; Wedge SR
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e447-54. PubMed ID: 22819210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward molecular imaging-driven drug development in oncology.
    de Vries EG; Oude Munnink TH; van Vugt MA; Nagengast WB
    Cancer Discov; 2011 Jun; 1(1):25-8. PubMed ID: 22586317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for thyroid cancer: An updated review of investigational agents.
    Deshpande HA; Gettinger SN; Sosa JA
    Curr Opin Investig Drugs; 2010 Jun; 11(6):661-8. PubMed ID: 20496261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?
    Fojo T; Parkinson DR
    Clin Cancer Res; 2010 Dec; 16(24):5972-80. PubMed ID: 21169250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication.
    Rask-Andersen M; Masuram S; Schiöth HB
    Annu Rev Pharmacol Toxicol; 2014; 54():9-26. PubMed ID: 24016212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects for non-immunological molecular therapeutics in melanoma.
    Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
    J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E; Masuda S; Kimura H
    J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.